GLPwatch
Orforglipron
Pipeline · Oral non-peptide GLP-1 receptor agonist
Last updated 2026-05-28Orforglipron is an experimental oral pill that works by mimicking a natural gut hormone called GLP-1, which helps control blood sugar and appetite. It is being studied in clinical trials but is not yet approved for any medical use.
AI summary of the sources below.
| Mechanism | Oral non-peptide GLP-1 receptor agonist A GLP-1 receptor agonist taken as a pill — mimics the gut hormone GLP-1 that lowers blood sugar and curbs appetite. |
|---|---|
| Status | Pipeline |
| Branded products | — (none approved) |
| Manufacturer(s) | eli-lilly |
How Orforglipron connects
Trials (28)
- A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
- A Drug-Drug Interaction Study of Orforglipron (LY3502970) With Quinidine in Healthy Participants
- A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)
- A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
- A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
- A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight
- A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants
- A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
- A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
- A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
- Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
- A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
- A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
- A Drug-Drug Interaction (DDI) Study of Orforglipron With Carbamazepine in Healthy Participants
- A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
- A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
- A Study to Compare Tablets and Capsules of Orforglipron (LY3502970) in Healthy Participants Who Are Obese or Overweight
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
- A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2
Top research (30)
- Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
- Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
- Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
- The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron.
- Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis.
- Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.
- Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.
- Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.
- Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
- Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.
- Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
- Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis.
- Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants.
- Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens.
- In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk.
- A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes.
- Orforglipron in type 2 diabetes mellitus and obesity: an overview.
- The efficacy and safety of danuglipron and orforglipron in patients with type 2 diabetes and obesity: a systematic review and meta-analysis.
- Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes.
- Methodological and statistical inconsistencies compromise the efficacy and safety analyses of orforglipron.